Business Monitor International


Thailand Pharmaceuticals & Healthcare Report

Published 30 October 2014

  • 115 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Thailand Pharmaceuticals & Healthcare Report

BMI View:   The stability brought about from the Junta will mitigate the uncertainty weighing down Thailand's pharmaceutical market. With its ageing population and universal healthcare, Thailand presents good market opportunities though risks stemming from cost containment policies and patent approval delays dampen the overall attractiveness.  

Headline Expenditure Projections

  • Pharmaceuticals: THB142.5bn (USD4.64bn) in 2013 to THB146bn (USD4.49bn) in 2014; +2.49% in local currency terms and -3.12% in US dollar terms.

  • Healthcare: THB473.3bn (USD15.4bn) in 2013 to THB506bn (USD15.5bn) in 2014; +6.93% in local currency terms and +1.08% in US dollar terms.

Risk/Reward Index: In Q1 2015, Thailand is ranked 12th out of the 19 key markets in Asia Pacific. While Thailand's score for its Industry Rewards variable is above the regional average (22.8 versus 21.8), indicating the country's favourable longer-term standing in terms of its pharmaceutical market development, operating risks - including the lacking intellectual property (IP) environment - remain elevated. 

Key Trends and Developments

  • In September, a meeting between Thailand and European business investors at an executive discussion forum organized by the Thai-European Business Association (TEBA) highlighted the renewed interest from Europe. Speakers from multiple businesses including GlaxoSmithKline suggested that Thailand was back on track with its newly appointed cabinet and prime minister.  

  • In September, Thailand's newly elected tourism minister outline goals to increase arrivals from neighbouring Southeast Asian nations. Included in the strategy are plans to promote the country's medical tourism sector.

  • On October 10 th, pharmacists in Thailand highlighted their opposition to a new draft bill for medicine to the country's Food and Drug Administration. According to the draft rules, multi-discipline health experts would be allowed to sell and import medicines without permission and...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Business Environment
15
Industry Forecast
17
Pharmaceutical Market Forecast
17
Table: Pharmaceutical Sales, Historical Data And Forecasts (Thailand 2010-2018)
18
Healthcare Market Forecast
18
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2010-2018)
21
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2010-2018)
22
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2010-2018)
22
Prescription Drug Market Forecast
23
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
26
Thailand
26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
27
Thailand
28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
29
Table: OTC Medicine Sales Indicators by Category, 2006-2008
29
Pharmaceutical Trade Forecast
30
Table: Pharmaceutical Trade Data And Forecasts (Thailand 2012-2018)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Thailand 2012-2018)
32
Other Healthcare Data
32
Key Risks To BMI's Forecast Scenario
33
Macroeconomic Forecasts
35
Economic Analysis
35
Table: Macroeconomic Forecasts (Thailand 2010-2016)
39
Industry Risk Reward Ratings
40
Asia Pacific Risk/Reward Ratings
40
Thailand Risk/Reward Ratings
46
Rewards
46
Risks
46
Market Overview
49
Industry Trends And Developments
50
Epidemiology
50
Communicable Diseases
51
Healthcare System
51
Healthcare Insurance
53
Recent Health Insurance Developments
54
Medical Tourism
56
Research And Development (R&D)
57
Biosimilars
59
Clinical Trials
60
Regulatory Development
62
Regulatory Regime
62
Regulatory Development
63
Regional Harmonisation
64
Intellectual Property Regime
65
IP Shortcomings
65
IP Developments
67
Pricing And Reimbursement
67
Table: Price Build-Up Of Medicines In Thailand
68
Competitive Landscape
70
Pharmaceutical Industry
70
Domestic Pharmaceutical Industry
71
Table: Pharmaceutical Manufacturers Of Modern Drugs, 2007-2012
72
Foreign Pharmaceutical Industry
72
Table: PReMA Members
72
Recent Pharmaceutical Industry Developments
72
Pharmaceutical Wholesale
74
Pharmaceutical Retail
75
Company Profile
78
Siam Pharmaceutical
78
Government Pharmaceutical Organisation
80
Biolab
84
Thai Meiji Pharmaceutical Company
86
Berlin Pharmaceutical Industry
88
Pfizer
90
Sanofi
93
GlaxoSmithKline
96
Merck & Co
99
Novartis
102
Demographic Forecast
105
Table: Thailand's Population By Age Group, 1990-2020 ('000)
106
Table: Thailand's Population By Age Group, 1990-2020 (% of total)
107
Table: Thailand's Key Population Ratios, 1990-2020
108
Table: Thailand's Rural And Urban Population, 1990-2020
108
Glossary
109
Methodology
111
Pharmaceutical Expenditure Forecast Model
111
Healthcare Expenditure Forecast Model
111
Notes On Methodology
112
Risk/Reward Ratings Methodology
113
Ratings Overview
114
Table: Pharmaceutical Risk/Reward Ratings Indicators
114
Indicator Weightings
115

The Thailand Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Thailand Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Thai pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Thailand to test other views - a key input for successful budgeting and strategic business planning in the Thai pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Thai pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Thailand.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc